Drug intelligence / Profile preview

Aborvac-S

Development stage: Unknown
Lead developer: Vetal Company
Modality: Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

Aborvac-S is a live attenuated veterinary vaccine developed by Vetal Company for the prevention of bovine brucellosis. It contains the *Brucella abortus* S19 strain, a stable, live-attenuated bacterium that induces active protective immunity against infection. The vaccine is available in two specific formulations: Aborvac-S Calf, intended for female calves aged 3 to 6 months, and Aborvac-S Cow, intended for adult cattle older than 6 months. It is used as a critical tool in livestock management to control and eradicate *Brucella abortus*, a pathogen responsible for significant reproductive losses, including abortion and infertility, in cattle populations.

Brand names: Aborvac-S
Other names: Aborvac-S CowAborvac-S Calf

Beyond the preview

Go deeper on Aborvac-S.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aborvac-S.

Explore the full profile